Merging our understanding of immune therapy with cutting-edge discoveries of how the microbiome functions, Rise is developing targeted immunotherapy drugs to treat a broad range of clinical indications. We utilize synthetic biology methodologies combined with strong product development experience and state-of-the-art clinical GMP manufacturing infrastructure allowing us to be a differentiated industry leader in novel immune medicine development.
The immune system is an important defense mechanism that protects us against a wide range of pathogens. Human immunology is a highly regulated and complex process that has evolved to allow us to distinguish host from pathogen.
Nowhere in the body is the immune system more ‘vibrant’ than along the intestinal tract where the majority of our microbiota reside. It is estimated that more immunological signals are processed in the gut in a single day than in the rest of our body in a lifetime.
Thus, it is no surprise that the gut immunological ecosystem and the immunological interface between the microbiota and the human immune cells have such important functionality on the local and systemic immune processes. In order for the microbiota to persist, the immune system must be held in check and prevented from attacking the very process that helps support our health and well-being.
As we better understand how these key processes work, we can design immunological-based drugs that can intervene to treat a variety of diseases including autoimmunity, cancer, and infection.
Synthetic biology utilizes rational design and construction of natural biological systems for useful product purposes.
At Rise Therapeutics, we use proprietary approaches to engineer novel immunological directed cellular products which direct targeted biological therapy. These products have broad applications in treating human disease.